4//SEC Filing
GNI Group Ltd. 4
Accession 0001140361-23-050569
CIK 0001124105other
Filed
Oct 30, 8:00 PM ET
Accepted
Oct 31, 9:56 PM ET
Size
10.3 KB
Accession
0001140361-23-050569
Insider Transaction Report
Form 4
GNI Group Ltd.
10% Owner
Transactions
- Purchase
Series X Convertible Preferred Stock
2023-10-27$4915.00/sh+811$3,986,065→ 13,151 total(indirect: See Footnote)→ Common Stock (811,000 underlying) - Purchase
Series X Convertible Preferred Stock Warrant (Right to Buy)
2023-10-27$0.13/sh+8,110,300$1,013,788→ 8,110,300 total(indirect: See Footnote)From: 2023-10-30Exp: 2033-10-30→ Series X Convertible Preferred Stock (811 underlying)
GNI USA, Inc.
10% Owner
Transactions
- Purchase
Series X Convertible Preferred Stock
2023-10-27$4915.00/sh+811$3,986,065→ 13,151 total(indirect: See Footnote)→ Common Stock (811,000 underlying) - Purchase
Series X Convertible Preferred Stock Warrant (Right to Buy)
2023-10-27$0.13/sh+8,110,300$1,013,788→ 8,110,300 total(indirect: See Footnote)From: 2023-10-30Exp: 2033-10-30→ Series X Convertible Preferred Stock (811 underlying)
Footnotes (4)
- [F1]Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022).
- [F2]The Preferred Stock has no expiration date.
- [F3]These securities are held by GNI USA, Inc., a Delaware corporation ("GNI USA") which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA.
- [F4]These warrants have an exercise price of $4,915.00 per share of Preferred Stock.
Documents
Issuer
GYRE THERAPEUTICS, INC.
CIK 0001124105
Entity typeother
Related Parties
1- filerCIK 0001958461
Filing Metadata
- Form type
- 4
- Filed
- Oct 30, 8:00 PM ET
- Accepted
- Oct 31, 9:56 PM ET
- Size
- 10.3 KB